Inés Portillo-Calderón

Inés Portillo-Calderón

Auto-generated profile, based on publicly available information

Inés Portillo-Calderón

Unidad de Gestión Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
MDM. Delgado-Valverde
M. Delgado-Valverde
IPI. Portillo-Calderón
I. Portillo-Calderón
ERE. Recacha
E. Recacha
PPPatricia Perez-Palacios
Patricia Perez-Palacios
APA. Pascual
A. Pascual
This article demonstrates the efficacy of cefiderocol against a large collection of well-characterized metallo-beta-lactamase-producing isolates, some of them even producing double carbapenemases. Furthermore, cefiderocol activity is compared to other novel broad-spectrum antimicrobials with activity against carbapenemases.

15 January 2017 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
MBM. Ballestero-Téllez
M. Ballestero-Téllez
FDFernando Docobo-Pérez
Fernando Docobo-Pérez
IPI. Portillo-Calderón
I. Portillo-Calderón
JRJosé Manuel Rodríguez-Martínez
José Manuel Rodríguez-Martínez
LRL. Racero
L. Racero
APA. Pascual
A. Pascual
Objectives: Fosfomycin activity in Escherichia coli depends on several genes of unknown importance for fosfomycin resistance. The objective was to characterize the role of uhpT, glpT, cyaA and ptsI genes in fosfomycin resistance in E. coli. Methods: WT E. coli BW25113 and null mutants, ΔuhpT, ΔglpT, ΔcyaA, ΔptsI, ΔglpT-uhpT, ΔglpT-cyaA, ΔglpT-ptsI, ΔuhpT-cyaA, ΔuhpT-ptsI and ΔptsI-cyaA, were studied. Susceptibility to fosfomycin was tested using CLSI guidelines. Fosfomycin mutant frequencies were determined at concentrations of 64 and 256 mg/L. Fosfomycin in vitro activity was tested using time–kill assays at concentrations of 64 and 307 mg/L (human Cmax). Results: Fosfomycin MICs were: WT E. coli BW25113 (2 mg/L), ΔglpT (2 mg/L), ΔuhpT (64 mg/L), ΔcyaA (8 mg/L), ΔptsI (2 mg/L), ΔglpT-uhpT (256 mg/L), ΔglpT-cyaA (8 mg/L), ΔglpT-ptsI (2 mg/L), ΔuhpT-cyaA (512 mg/L), ΔuhpT-ptsI (64 mg/L) and ΔptsI-cyaA (32 mg/L). In the mutant frequency assays, no mutants were recovered from BW25113. Mutants appeared in ΔglpT, ΔuhpT, ΔcyaA and ΔptsI at 64 mg/L and in ΔuhpT and ΔcyaA at 256 mg/L. ΔglpT-ptsI, but not ΔglpT-cyaA, ΔuhpT-cyaA or ΔuhpT-ptsI, increased the mutant frequency compared with the highest frequency found in each single mutant. In time–kill assays, all mutants regrew at 64 mg/L. Initial bacterial reductions of 2–4 log10 cfu/mL were observed for all strains, except for ΔuhpT-ptsI, ΔglpT-uhpT and ΔuhpT-cyaA. Only ΔglpT and ΔptsI mutants were cleared using 307 mg/L. Conclusions: Fosfomycin MIC may not be a good efficacy predictor, as highly resistant mutants may appear, depending on other pre-existing mutations with no impact on MIC.

29 December 2023 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
MDMercedes Delgado-Valverde
Mercedes Delgado-Valverde
IPInés Portillo-Calderón
Inés Portillo-Calderón
MAManuel Alcalde-Rico
Manuel Alcalde-Rico
MCM. Carmen Conejo
M. Carmen Conejo
CHCarmen Hidalgo
Carmen Hidalgo
ÁPÁlvaro Pascual
Álvaro Pascual
Purpose: Relebactam is a novel β-lactamase inhibitor, which, when combined with imipenem/cilastatin, is active against both class A and class C β-lactamases. To evaluate in vitro antimicrobial activity of imipenem/relebactam against a collection of recent clinical isolates of carbapenem-non-susceptible P. aeruginosa and K. pneumoniae ST258 and ST512 KPC producers belonging to different lineages from hospitals in Southern Spain. Methods: Six hundred and seventy-eight isolates were tested: 265 K. pneumoniae (230 ST512/KPC-3 and 35 ST258/KPC-3) and 413 carbapenem-non-susceptible P. aeruginosa. Imipenem, piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, ceftolozane/tazobactam, meropenem, amikacin, ciprofloxacin, colistin, and ceftazidime/avibactam were used as comparators against P. aeruginosa. Against K. pneumoniae ceftazidime, cefepime, aztreonam, and ceftolozane/tazobactam were not tested, and tigecycline was studied instead. MICs were determined in duplicate by broth microdilution according to EUCAST guidelines. Results: Imipenem/relebactam displayed potent in vitro activity against both sequence types of KPC-3-producing K. pneumoniae. MIC50 and MIC90 values were 0.25 mg/L and 1 mg/L, respectively, with percent of susceptible isolates >97%. Only three K. pneumoniae ST512/KPC-3 isolates and one ST258/KPC-3 were resistant to imipenem/relebactam. Relebactam sensitized 98.5% of K. pneumoniae isolates resistant to imipenem. The activity of imipenem/relebactam against P. aeruginosa was moderate (susceptibility rate: 62.7%). Analysis of the acquired and mutational resistome of isolates with high levels of resistance to imipenem/relebactam has not shown a clear association between them. Conclusion: Imipenem/relebactam showed excellent activity against K. pneumoniae KPC-3. The activity of imipenem/relebactam against imipenem-resistant P. aeruginosa was moderate.

3 September 2025 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
LSLucía Sánchez-Peña
Lucía Sánchez-Peña
SRSalud Rodríguez-Pallares
Salud Rodríguez-Pallares
PAPablo Aja-Macaya
Pablo Aja-Macaya
TBTania Blanco-Martín
Tania Blanco-Martín
LGLucía González-Pinto
Lucía González-Pinto
JAJorge Arca-Suarez
Jorge Arca-Suarez
Xeruborbactam is a broad-spectrum boronate-type β-lactamase inhibitor. We aimed to evaluate its activity in combination with meropenem and compare it with other β-lactam/β-lactamase inhibitor combinations against Enterobacterales. The following isolates were screened: (i) an isogenic collection of 94 Escherichia coli isolates producing β-lactamases under wild-type and low-permeability conditions, (ii) 300 genetically diverse clinical Enterobacterales isolates producing the three main carbapenemase types (KPC-like, OXA-48-like, and metallo-β-lactamases), and (iii) two collections of isolates producing mechanisms of resistance to β-lactam/β-lactamase inhibitor combinations, such as KPC variants or PBP3 insertions combined with metallo-β-lactamases (MBLs). The MICs of meropenem, meropenem/xeruborbactam, meropenem/vaborbactam, imipenem, imipenem/relebactam, cefepime, cefepime/taniborbactam, ceftazidime, ceftazidime/avibactam, aztreonam, and aztreonam/avibactam were determined by reference broth microdilution and interpreted following the European Committee on Antimicrobial Susceptibility Testing guidelines, using the breakpoint of the β-lactam alone for not yet approved combinations. Resistance mechanisms of all clinical isolates were analyzed by whole genome sequencing. Meropenem/xeruborbactam had the broadest spectrum against the isogenic collection, although higher MICs were noted for transformants producing IMP-23, SPM-1, and NDM enzymes (these latter only when produced under low-permeability conditions). Meropenem/xeruborbactam displayed the most potent activity against the collection of 300 clinical strains (MIC 50/90 ≤0.06/≤0.06 mg/L). Xeruborbactam restored meropenem activity against the strains carrying resistance mechanisms to β-lactam/β-lactamase inhibitor combinations, including strains producing KPC variants or MBLs in combination with additional chromosomal alterations (MIC range: ≤0.06–0.25 and ≤0.06–4 mg/L, respectively). Our findings highlight the potential of xeruborbactam in combination with meropenem as a promising treatment against carbapenemase-producing Enterobacterales, including strains with emerging resistance to other β-lactam/β-lactamase inhibitor combinations.

22 May 2020 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
IPInés Portillo-Calderón
Inés Portillo-Calderón
MPMIRIAM ORTIZ PADILLA
MIRIAM ORTIZ PADILLA
JRJosé Manuel Rodríguez-Martínez
José Manuel Rodríguez-Martínez
BGBelen de Gregorio-Iaria
Belen de Gregorio-Iaria
JBJesús Blázquez
Jesús Blázquez
FDFernando Docobo-Pérez
Fernando Docobo-Pérez
Objectives: To explore the effect of combining defects in DNA repair systems with the presence of fosfomycin-resistant mechanisms to explain the mechanisms underlying fosfomycin heteroresistance phenotypes in Enterobacteriaceae.Materials and methods: We used 11 clinical Escherichia coli isolates together with isogenic single-gene deletion mutants in the E. coli DNA repair system or associated with fosfomycin resistance, combined with double-gene deletion mutants. Fosfomycin MICs were determined by gradient strip assay (GSA) and broth microdilution (BMD). Mutant frequencies for rifampicin (100 mg/L) and fosfomycin (50 and 200 mg/L) were determined. Using two starting inocula, in vitro fosfomycin activity was assessed over 24 h in growth (0.5–512 mg/L) and time–kill assays (64 and 307 mg/L).Results: Strong and weak mutator clinical isolates and single-gene deletion mutants, except for ΔuhpT and ΔdnaQ, were susceptible by GSA. By BMD, the percentage of resistant clinical isolates reached 36%. Single-gene deletion mutants showed BMD MICs similar to those for subpopulations by GSA. Strong mutators showed a higher probability of selecting fosfomycin mutants at higher concentrations. By combining the two mechanisms of mutation, MICs and ranges of resistant subpopulations increased, enabling strains to survive at higher fosfomycin concentrations in growth monitoring assays. In time–kill assays, high inocula increased survival by 37.5% at 64 mg/L fosfomycin, compared with low starting inocula.Conclusions: The origin and variability of the fosfomycin heteroresistance phenotype can be partially explained by high mutation frequencies together with mechanisms of fosfomycin resistance. Subpopulations should be considered until clinical meaning is established.

19 April 2021 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
IPI. Portillo-Calderón
I. Portillo-Calderón
MPMIRIAM ORTIZ PADILLA
MIRIAM ORTIZ PADILLA
BGB. de Gregorio-Iaria
B. de Gregorio-Iaria
VMV. Merino-Bohorquez
V. Merino-Bohorquez
Jesus BlazquezJesus Blazquez
Jesus Blazquez
FDFernando Docobo-Pérez
Fernando Docobo-Pérez
Objectives: To evaluate human-like intravenous doses of fosfomycin (8g/Q8h) and amikacin (15mg/kg/Q24h) efficacy in monotherapy and in combination against six fosfomycin-heteroresistant Escherichia coli isolates using a hollow-fiber infection model (HFIM). Materials and methods: Six fosfomycin-heteroresistant E. coli isolates (4 with strong mutator phenotype) and the control strain E. coli ATCC 25922 were used. Mutant frequencies for rifampin (100mg/L), fosfomycin (50 and 200mg/L) and amikacin (32mg/L) were determined. Fosfomycin and amikacin MICs were assessed by agar dilution (AD), gradient strip (GSA) and broth microdilution (BMD) assays. Fosfomycin and amikacin synergies were studied by checkerboard and time-kill assays at different concentrations. Fosfomycin (8g/Q8h) and amikacin (15mg/kg/Q24h) efficacy alone and in combination were assessed using a HFIM. Results: Five isolates were resistant to fosfomycin by AD and BMD, but all susceptible by GSA. All isolates were considered susceptible to amikacin. Antibiotic combinations were synergistic in two isolates and no antagonism was detected. In time-kill assays, all isolates survived under fosfomycin at 64mg/L, although, at 307mg/L, only the normomutators and two hypermutators survived. Four isolates survived under 16mg/L amikacin and none at 45mg/L. No growth was detected under combination conditions. In HFIM, fosfomycin and amikacin monotherapies failed to sterilise bacterial cultures, however, fosfomycin and amikacin combination showed a rapid eradication. Conclusions. There may be a risk of treatment failure of fosfomycin-heteroresistant E. coli isolates using either amikacin or fosfomycin in monotherapy. These results support that the combination amikacin-fosfomycin can rapidly decrease bacterial burden and prevent the emergence of resistant subpopulations against fosfomycin-heteroresistant strains.